GPhA’s Drug Shortage Initiative Clears FTC Hurdle; Still Working With FDA

The Generic Pharmaceutical Association is on track to launch its drug shortage monitoring program after getting a green light from the Federal Trade Commission.

The association requested an advisory opinion from FTC as to whether its proposed Accelerated Recovery Initiative (ARI) would harm competition. Under this program a third party, IMS Health Inc., is to collect information from manufacturers about their projected production and supply schedules of drugs in short supply and give the data to FDA